Rana A, Samtiya M, Dhewa T, Mishra V, Aluko RE
Eur J Pharmacol 793:5665 Acknowledgements This research was supported by the Ministry of Science, Education and Sports, Republic of Croatia (Grant Number 108-1083570-3635)
Licensed indications 2,3 2,3 Subcutaneous semaglutide (Wegovy) and tirzepatide (Mounjaro) are indicated as adjuncts to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial BMI of: 30 kg/m 2 (obesity), or 27 kg/m 2 to 2 days away, administer as soon as possible
Additionally, as part of the broader evidence program, a set of Phase IIIb studies are being advanced to address key unmet needs in people living with obesity and real-world care